Frontier Bio develops complex lab-grown lung tissue using 3D bioprinting and stem cell tech that will also aid respiratory disease research.
In a significant step forward for medical science, Frontier Bio Corporation announced today the development of lab-grown lung tissue that closely mimics the natural architecture of human lungs. Using a combination of 3D bioprinting, a proprietary blend of biomaterials and stem cell self-assembly, the California-based company has created microscale lung tissue capable of replicating key functions of the human respiratory system.
Longevity.Technology: This development has the potential to advance therapeutic research in respiratory diseases and, looking further ahead, may offer solutions to the global organ transplant shortage – a problem that affects hundreds of thousands of individuals worldwide. The US alone has over 100,000 on transplant waiting lists, and yet the availability of organs continues to fall short [1]. Many people die from organ failure before they even make it to a transplant list.
Enter Frontier Bio, whose innovation marks a notable shift in the field of biomedical research. As well as having the future goal of transplantable tissue in it sights, it is also focused on tech that can be put to swift use. While animal models have long been used in preclinical drug testing, these often fail to capture the full complexity of human biology, leading to high failure rates when new treatments move to human trials. Frontier Bio’s creation of lab-grown lung tissue, constructed from human cells combined with biomaterials , offers a more precise model for understanding disease progression and evaluating the efficacy of new drugs and will mean therapies can move out of the lab and into clinic more quickly.
“There is an urgent need for more accurate models of lung tissue that allow us to test new therapeutics more effectively than with current methods,” said Victoria-Elisabeth Gruber, Head of Translational Research at Frontier Bio.
The development of this lung tissue, according to the company, involved a proprietary process that combines human cells with biomaterials designed to guide the self-organization of the cells into the intricate structures of the distal lung. These biomaterials not only support the structural integrity of the tissue but also promote cell differentiation and mimic the natural environment of the lungs. As the cells self-assemble, they form key lung structures such as bronchioles, alveolar air sacs and beating cilia – the latter of which are essential for keeping natural airways clear.
Unlike many other lab-grown tissues, this model has the capability to produce both mucus and surfactant (a substance that reduces the surface tension of moisture in the lungs, helps it spread out and wet the necessary surfaces). These are both essential components of lung function, and this ability to replicate not only structural elements but also functional aspects of the lung is critical for creating accurate models for drug testing, especially for diseases like lung cancer, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis and the acute impacts of COVID-19.
The lab-grown lung tissue could eventually be used as a foundation for developing full-scale organs for transplantation. With over 35 million Americans suffering from chronic lung diseases [2], the need for replacement tissue is pressing; moreover, many patients face years-long waits for donor organs, with some dying before a match is found.
In addition to its promise for transplantation, Frontier Bio’s technology could serve as a platform for testing new drugs more efficiently. The $70 billion respiratory disease market stands to benefit from more accurate testing models, which could reduce the costly process of drug development. The current reliance on animal models frequently leads to unexpected failures in human trials, and Frontier Bio’s approach seeks to mitigate this by more closely mimicking human lung tissue dynamics.
The company has already seen promising results in its work on other tissue types. In collaboration with the Mayo Clinic, and supported by a National Science Foundation grant, Frontier Bio has made advances in lab-grown blood vessels and neural tissues, providing a broader proof of concept for its bioprinting and stem cell-driven approaches.
As the company continues to refine its lung tissue models, it is also exploring partnerships to extend the reach of its technology into therapeutic applications.
“Frontier Bio is doing more than just creating lab-grown human tissues. They’re paving the way for a future where organ donors are no longer needed, and animal testing is a thing of the past,” noted George Church, a pioneering geneticist and advisor to the company.
Given the potential of lab-grown lung tissue for both drug testing and organ transplantation, we asked Eric Bennett, CEO of Frontier Bio, how he sees this technology evolving over the next decade.
He told us that the tech starts with small-scale applications like drug testing, toxicity screening and disease modeling – areas where lab-grown lung tissue can make an immediate impact.
“As we progress, it will support more complex uses such as studying lung diseases in individuals to enable personalized medicine,” he explained. “One of the main challenges is scaling up to larger tissues while maintaining consistent quality. To overcome this, we’ll be leveraging advanced bioreactor technology that emerged from the cellular agriculture boom, allowing us to create human-sized lung tissue with intricate branching and full lung capacity.”
Bennett added that other hurdles, like achieving full vascularization and ensuring immune compatibility, are being addressed through ongoing bioengineering innovations.
“These advancements are set to revolutionize organ transplantation – giving hope to thousands of patients waiting for lifesaving treatment – and could redefine the future of healthcare.”
While this vision may take years to fully materialize, the early successes achieved by Frontier Bio highlight the potential for lab-grown tissues to transform both disease treatment and the organ transplant system. There remains, of course, a long path ahead before lab-grown organs can be routinely used in clinical settings; however, the capacity of this technology to replicate complex human tissues opens up new avenues for research and therapy development. Beyond respiratory diseases, the ability to create functional human tissues in the lab has implications for a wide range of medical conditions, from cardiovascular diseases to neurological disorders. While still in its early stages, Frontier Bio’s innovative technology could be a critical tool for researchers and clinicians alike, helping to bridge the gap between experimental treatments and successful clinical outcomes.
[1] https://www.organdonor.gov/learn/organ-donation-statistics
[2] https://www.lung.org/about-us/our-impact
